A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (NCT01896479)
A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
🩺 Plain-English Summary (8th-Grade Level)
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Facility — St Leonards, New South Wales
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (49 Sites)
Showing the first 25 of 49 sites.
- Clinical Research Facility — St Leonards, New South Wales
- Clinical Research Facility — Herston, Queensland
- Clinical Research Facility — Kurralta Park, South Australia
- Clinical Research Facility — Parkville, Victoria
- Clinical Research Facility — Québec, Quebec
- Clinical Research Facility — Toronto,
- Clinical Research Facility — Osijek,
- Clinical Research Facility — Zagreb,
- Clinical Research Facility — Zagreb,
- Clinical Research Facility — Bordeaux, Gironde
- Clinical Research Facility — Angers, Maine-et-Loire
- Clinical Research Facility — Lyon, Rhône
- Clinical Research Facility — Villejuif, Val-de-Marne
- Clinical Research Facility — Dijon,
- Clinical Research Facility — Paris,
- Clinical Research Facility — Strasbourg,
- Clinical Research Facility — Budapest,
- Clinical Research Facility — Debrecen,
- Clinical Research Facility — Jerusalem,
- Clinical Research Facility — Petah Tikva,
- Clinical Research Facility — Safed,
- Clinical Research Facility — Catania, CT
- Clinical Research Facility — Roma, RM
- Clinical Research Facility — Siena, SI
- Clinical Research Facility — Pisa, Tuscany
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Medullary Thyroid Cancer
- A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — Birmingham, Alabama
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors — Los Angeles, California
- A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study — San Francisco, California
- Natural History Study of Children and Adults With Medullary Thyroid Cancer — Bethesda, Maryland
Explore by condition: All Medullary Thyroid Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.